Compare SANG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANG | NNNN |
|---|---|---|
| Founded | 1984 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.1M | 163.7M |
| IPO Year | 2018 | 2023 |
| Metric | SANG | NNNN |
|---|---|---|
| Price | $4.66 | $3.80 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.54 | N/A |
| AVG Volume (30 Days) | ★ 127.9K | 46.5K |
| Earning Date | 11-13-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.40 | $3.09 |
| 52 Week High | $5.42 | $44.73 |
| Indicator | SANG | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 33.42 |
| Support Level | $4.64 | $3.09 |
| Resistance Level | $5.02 | $6.95 |
| Average True Range (ATR) | 0.11 | 0.45 |
| MACD | -0.05 | 0.10 |
| Stochastic Oscillator | 44.74 | 39.17 |
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic location USA and Other countries. Key revenue is generated from USA.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).